NCT00510354View on ClinicalTrials.gov

Treatment of Patients With Everolimus and Imatinib Mesylate Who Have Progressive Gastro Intestinal Stromal Tumors (GIST) and Are Resistant to Imatinib Mesylate

PHASE4CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions
Progressive Gastrointestinal Stromal Tumor
Interventions
DRUG

Imatinib mesylate

Trial Locations (7)

13125

Novartis Investigative Site, Berlin

30625

Novartis Investigative Site, Hanover

45122

Novartis Investigative Site, Essen

60488

Novartis Investigative Site, Frankfurt

60590

Novartis Investigative Site, Frankfurt/M

68167

Novartis Investigative Site, Mannheim

72076

Novartis Investigative Site, Tübingen

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY